Evidence Reports of Kampo Treatment

Task Force for Evidence Reports, the Japan Society for Oriental Medicine
Note) The quality of this RCT has not been validated by the EBM committee of the Japan Society for Oriental Medicine.

10. Respiratory Diseases (including Influenza and Rhinitis)

Reference

Kimoto H, Kuroki H. Efficacy of combined administration of oseltamivir phosphate and maoto in treating influenza. *Kampo Igaku (Kampo Medicine)* 2005; 29: 166-9 (in Japanese). Ichushi Web ID: 2005292428

1. Objectives

To evaluate the efficacy of maoto (麻黄湯) in combination with oseltamivir phosphate in treating pediatric influenza.

2. Design

Quasi-randomized controlled trial (quasi-RCT).

3. Setting

An internal medicine clinic screening patients from January to March 2004, Japan.

4. Participants

Adult patients (n=37) positive for influenza (rapid diagnostic test), and having fever (≥38°C) within 48 hours of onset.

5. Intervention

Nineteen out of 37 subjects were included in the sample. Eighteen subjects were excluded because of body temperature not more than 38°C (n=5), being on a drip (n=1), preference for Kampo formulae only (n=5), preference for Western drugs only (n=2), cognitive impairment (n=1), refusal to give consent to participate in the study (n=1), and regular use of Kampo formulae (n=3).

Oseltamivir phosphate (75 mg b.i.d. for 5 days), TSUMURA Maoto (麻黄湯) Extract Granules 2.5 g t.i.d. for 3 days), and Western medicines (an antihistamine [cyproheptadine hydrochloride] with either a bronchodilator [clenbuterol hydrochloride] or expectorant [carbocysteine]) were administered for 3 days. Treatment assignment was chronological according to examination date.

Arm 1: oseltamivir phosphate and maoto (麻黄湯), n=10.

Arm 2: oseltamivir phosphate and Western medicines, n=9.

6. Main outcome measures

Body temperature.

The magnitude and time course of symptoms such as appetite, fatigue, and dizziness/light-headedness.

7. Main results

All subjects studied were infected with influenza A. Patients in arm 1 tended to become afebrile 12 hours earlier than patients in arm 2. There were no significant between-group differences in anorexia, fatigue, and dizziness/light-headedness, though patients in arm 1 tended to improve more rapidly than patients in arm 2.

8. Conclusions

Compared with oseltamivir plus Western formulations, oseltamivir plus Kampo formulation (maoto) tended to shorten the duration of fever and allowed patients to maintain normal activity.

9. From Kampo medicine perspective

None.

10. Safety assessment in the article

There were no adverse events in any group.

11. Abstractor's comments

The graph shows that 12 hours after administration, fever dropped below 38°C in the maoto (麻黄湯) group, and temperature was a little above 38.5°C in the Oseltamivir phosphate-only group, which was a significant difference. After 24 hours, body temperature was about 37.5°C in both groups. However, no other clear differences in symptoms were observed between the two groups. Most of the adult participants commented that they felt more comfortable on the day after taking Oseltamivir phosphate, but adults are commonly prescribed acetaminophen in single doses as an antipyretic analgesic, and significantly, the study found that patients experienced fever as part of the natural course after administration. Exceptional cases may be excluded from the total number of cases.

12. Abstractor and date

Fujisawa M. 15 June 2007, 1 April 2008, 9 March, 1 June 2010, 31 December 2013.